Copyright
©The Author(s) 2024.
World J Clin Cases. Dec 26, 2024; 12(36): 6892-6904
Published online Dec 26, 2024. doi: 10.12998/wjcc.v12.i36.6892
Published online Dec 26, 2024. doi: 10.12998/wjcc.v12.i36.6892
Figure 1 Oral blood pressure augmenting agents’ mechanism of action.
A1: Alpha1; AADC: Aromatic amino acid decarboxylase; ADP: Adenosine diphosphate; ATP: Adenosine triphosphate; Ca2+: Calcium cation; DAG: Diacylglycerol; DG: Deglycination; IP3: Inositol-1,4,5-triphosphate; MLC: Myosin light chain; MLCK: Myosin light chain kinase; MLCP: Myosin light chain phosphatase; P: Phosphorus; PIP2: Phosphatidylinositol-4,5-bisphosphate; PLC: Phospholipase C; SR: Sarcoplasmic reticulum.
- Citation: Robinson JC, ElSaban M, Smischney NJ, Wieruszewski PM. Oral blood pressure augmenting agents for intravenous vasopressor weaning. World J Clin Cases 2024; 12(36): 6892-6904
- URL: https://www.wjgnet.com/2307-8960/full/v12/i36/6892.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i36.6892